ATE443262T1 - Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen - Google Patents
Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchenInfo
- Publication number
- ATE443262T1 ATE443262T1 AT05766758T AT05766758T ATE443262T1 AT E443262 T1 ATE443262 T1 AT E443262T1 AT 05766758 T AT05766758 T AT 05766758T AT 05766758 T AT05766758 T AT 05766758T AT E443262 T1 ATE443262 T1 AT E443262T1
- Authority
- AT
- Austria
- Prior art keywords
- dementia
- treatment
- uch
- molecular diagnosis
- lewy body
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title 1
- 210000004558 lewy body Anatomy 0.000 title 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 3
- 201000002832 Lewy body dementia Diseases 0.000 abstract 3
- 208000032859 Synucleinopathies Diseases 0.000 abstract 1
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 abstract 1
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401764A ES2310057B1 (es) | 2004-07-19 | 2004-07-19 | Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy. |
| PCT/EP2005/007813 WO2006008124A2 (en) | 2004-07-19 | 2005-07-18 | Molecular diagnostic method and treatment in dementia with lewy bodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE443262T1 true ATE443262T1 (de) | 2009-10-15 |
Family
ID=35785587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05766758T ATE443262T1 (de) | 2004-07-19 | 2005-07-18 | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7745127B2 (de) |
| EP (1) | EP1787127B1 (de) |
| JP (1) | JP2008506406A (de) |
| AT (1) | ATE443262T1 (de) |
| AU (1) | AU2005263583A1 (de) |
| CA (1) | CA2574224A1 (de) |
| DE (1) | DE602005016697D1 (de) |
| ES (2) | ES2310057B1 (de) |
| WO (1) | WO2006008124A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2175246B1 (de) * | 2008-10-09 | 2017-07-19 | Sensirion AG | Verfahren zur Messung eines Parameters einer Fluidzusammensetzung mithilfe eines Flusssensors |
| EP2204555B1 (de) * | 2009-01-02 | 2011-08-03 | Sensirion AG | Ammoniakspeichersystem |
| KR101384642B1 (ko) * | 2012-06-22 | 2014-04-22 | 이화여자대학교 산학협력단 | Ｎ―말단이 제거된 유비퀴틴 ｃ―말단 가수분해효소―ｌ１（ｎｔ―ｕｃｈ―ｌ１）를 유효성분으로 포함하는 파킨슨병 예방 및 치료용 약학적 조성물 |
| KR102450182B1 (ko) * | 2016-01-05 | 2022-10-04 | 엘지전자 주식회사 | 세탁물처리장치 및 그의 세탁제공급방법 |
| CN112111529A (zh) * | 2019-06-21 | 2020-12-22 | 上海市计划生育科学研究所 | 神经退行性疾病动物模型及其建立与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3117799A (en) * | 1998-03-30 | 1999-10-18 | Trustees Of The University Of Pennsylvania, The | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
| US20040014142A1 (en) * | 1998-07-03 | 2004-01-22 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| GB0203446D0 (en) | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
| AU2003253014A1 (en) * | 2002-06-21 | 2004-01-06 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
| EP1675948A2 (de) * | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte behandlung von morbus parkinson unter verwendung von sina (short interfering nucleic acid) |
-
2004
- 2004-07-19 ES ES200401764A patent/ES2310057B1/es not_active Withdrawn - After Issue
-
2005
- 2005-07-18 JP JP2007521880A patent/JP2008506406A/ja active Pending
- 2005-07-18 AT AT05766758T patent/ATE443262T1/de not_active IP Right Cessation
- 2005-07-18 ES ES05766758T patent/ES2333660T3/es not_active Expired - Lifetime
- 2005-07-18 EP EP05766758A patent/EP1787127B1/de not_active Expired - Lifetime
- 2005-07-18 AU AU2005263583A patent/AU2005263583A1/en not_active Abandoned
- 2005-07-18 US US11/658,057 patent/US7745127B2/en not_active Expired - Fee Related
- 2005-07-18 WO PCT/EP2005/007813 patent/WO2006008124A2/en not_active Ceased
- 2005-07-18 DE DE602005016697T patent/DE602005016697D1/de not_active Expired - Lifetime
- 2005-07-18 CA CA002574224A patent/CA2574224A1/en not_active Abandoned
-
2010
- 2010-05-11 US US12/800,290 patent/US20100285483A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005263583A1 (en) | 2006-01-26 |
| ES2310057B1 (es) | 2009-11-17 |
| EP1787127B1 (de) | 2009-09-16 |
| US7745127B2 (en) | 2010-06-29 |
| CA2574224A1 (en) | 2006-01-26 |
| EP1787127A2 (de) | 2007-05-23 |
| DE602005016697D1 (de) | 2009-10-29 |
| US20100285483A1 (en) | 2010-11-11 |
| ES2310057A1 (es) | 2008-12-16 |
| JP2008506406A (ja) | 2008-03-06 |
| WO2006008124A2 (en) | 2006-01-26 |
| US20090028845A1 (en) | 2009-01-29 |
| WO2006008124A3 (en) | 2006-05-18 |
| ES2333660T3 (es) | 2010-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123503T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| ATE550338T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| DE602004024909D1 (de) | Platinkomplexe zur behandlung von tumoren | |
| ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| EP1916964A4 (de) | Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten | |
| ATE524479T1 (de) | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren | |
| DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
| EP1742675A4 (de) | Behandlung von biomedizinischem abfall | |
| ATE512948T1 (de) | Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen | |
| DE602005019247D1 (de) | Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen | |
| DE602006003538D1 (de) | Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes | |
| ATE446754T1 (de) | Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten | |
| ATE529427T1 (de) | Ä1h-indol-5-yl)-heteroaryloxyü-(1-aza-bicyclo- ä3.3.1ü-nonane als cholinergische liganden des n- achr zur behandlung psychotischer und neurodegenerativer leiden | |
| DE602005012481D1 (de) | 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck | |
| DE602004022153D1 (de) | Verbindungen zur behandlung von obesitas | |
| EP1905452A4 (de) | Wirkstoff zur prävention oder behandlung von glaukomen | |
| NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
| ATE542535T1 (de) | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten | |
| DE602005016697D1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen | |
| ATE410166T1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit | |
| DE602005027251D1 (de) | Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |